Trailing Twelve Months Revenue Growth: Cyclacel, Inc. (CYCC)

Public company logo of cyclacel.com (CYCC)

Cyclacel Pharmaceuticals (CYCC) develops precision cancer treatments, competing for capital during early-stage development. The year-over-year revenue dynamics over the last 12 months reflect current market positions, where the value of 0.00 captures the metric level. The issuer's prospects rely on the efficacy of CDK inhibitors in treating solid tumors and leukemia, which determines the future scale of the business.

Cyclacel Pharmaceuticals (CYCC): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 02/20/2024

Cyclacel Pharmaceuticals - analytical breakdowns and key metrics (CYCC)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Cyclacel Pharmaceuticals Inc.
Brand item of Cyclacel, Inc.

For Cyclacel Pharmaceuticals (CYCC), which develops therapies for solid tumors and leukemia, revenue dynamics depend critically on the clinical trial stages of new molecules. By analyzing the YoY revenue growth rate over a rolling 12-month period, an investor assesses the percentage change in income over the last four quarters, allowing for the rapid identification of product commercialization trends before the release of official annual reports and confirming the business's financial stability.

Who Cyclacel Pharmaceuticals competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) BioLineRx Corporation (BLRX)|Sales Growth YoY (Last Twelve Months) Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Trailing Twelve Months Sales Growth|KZIA: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth Silexion Therapeutics|NuCana plc (NCNA) - Sales Growth YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) Chimerix, Inc|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)